Allurion Q3 revenue $5.4M, down 70% YoY; FY2024 guidance cut to $30-35M

ALLURION TECHNOLOGIES, INC.

2024-Q3 EPS reported -$0.10 revenue$26,519,000

Revenue $5.4M vs $18.2M prior year, includes $1.2M France recall charge; gross margin fell to 58% from 77%.
Full-year 2024 revenue guidance lowered to $30-35M; expects flat procedure volume growth YoY.
Restructuring reduces workforce & opex ~50%; $3.5M charges in Q4, targeting profitability by end of 2025.
AI VCS revenue up 82% YoY; AUDACITY top-line readout expected by year-end after last patient exited.
Three of four PMA modules filed for Allurion Balloon; France remediation plan completed in September.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.